Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sight Sciences Inc (NQ: SGHT )

5.100 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sight Sciences Inc

< Previous 1 2 3 4 5 6 Next >
Dow Falls 75 Points; US Small Business Optimism Drops In August
U.S. stocks traded lower this morning, with the Dow Jones falling around 75 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.22% to 34,587.58 while the NASDAQ fell 0.21%... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Glaucoma Player Sight Sciences Stock Falls More Than 30%: Analyst Warns Of Lingering Concerns Over Coverage
Sight Sciences Inc (NASDAQ: SGHT) shares are trading lower after the company issued third-quarter total revenue guidance below estimates and cut full-year 2023 revenue  
Via Benzinga
Adobe To Rally Over 14%? Here Are 10 Other Analyst Forecasts For Tuesday
RBC Capital boosted the price target for CareTrust REIT, Inc. (NYSE: CTRE) from $19 to $23. RBC Capital analyst Michael Carroll upgraded the stock from Sector Perform to Outperform. CareTrust REIT... 
Via Benzinga
What 6 Analyst Ratings Have To Say About Sight Sciences
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Analyst Expectations for Sight Sciences's Future
Via Benzinga
Recap: Sight Sciences Q1 Earnings
Via Benzinga
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
Oracle, Sight Sciences And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Sight Sciences Stock Traded Lower Today
Sight Sciences, Inc. (NASDAQ: SGHT) shares traded lower Monday after the company issued third-quarter total revenue guidance below estimates and cut full-year 2023 revenue 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
Via Benzinga
Why Metropolitan Bank Holding Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Digital World Acquisition Corp. (NASDAQ: DWAC) jumped 69% to $22.59 after the company announced it reached a settlement with the SEC. 
Via Benzinga
Scholastic, Matson, Digital World Acquisition And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 90 points on Friday. Here are some big stocks recording gains in today’s session. Digital World Acquisition Corp. (NASDAQ: DWAC) climbed 69%... 
Via Benzinga
Sight Sciences' TearCare Surpasses Restasis Dry Eye Treatment, Trial Data shows
Sight Sciences Inc (NASDAQ: SGHT) released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis  
Via Benzinga
Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 10, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023
Via Benzinga
BlackRock To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Keybanc raised the price target for BILL Holdings, Inc. (NYSE: BILL) from $110 to $140. Keybanc analyst Josh Beck maintained an Overweight rating. BILL Holdings shares fell 2.3% to $113.00 in... 
Via Benzinga
Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
From Sight Sciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Sight Sciences' Cataract Surgery Tech Shows Consistent Lowering Of Eye Pressure, Medication Use
Sight Sciences Inc (NASDAQ: SGHT) published two-year results of the so-called "Romeo" study of the OMNI Surgical System. 
Via Benzinga
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical
From Sight Sciences, Inc.
Via GlobeNewswire
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
Patients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract... 
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023
From Sight Sciences, Inc.
Via GlobeNewswire
Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Clinical data includes long-term trial results and robust real-world comparative data from IRIS® Registry 
From Sight Sciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.